{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T12:57:48Z","timestamp":1790859468260,"version":"4.1.0"},"reference-count":0,"publisher":"The Journal of Rheumatology","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the achievement of minimal disease activity (MDA) and very low disease activity (VLDA) in patients with psoriatic arthritis (PsA) treated in a real-world clinical setting with biologic\/targeted synthetic disease-modifying antirheumatic drugs (b\/tsDMARDs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study included patients with a diagnosis of PsA treated with an approved b\/tsDMARD and enrolled in the CorEvitas PsA\/Spondyloarthritis (SpA) Registry (March 2013-September 2023). MDA\/VLDA achievement was assessed at the follow-up registry visit, 6 (range: 5-9) months post index (b\/tsDMARD initiation).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At the follow-up registry visit, 17.68% (370\/2093) and 7.51% (187\/2491) of patients achieved MDA and VLDA, respectively. Baseline characteristics, including female sex, higher baseline fatigue and pain scores, and previous treatment with b\/tsDMARDs were associated with a lower likelihood of achieving MDA\/VLDA. Higher EQ-5D-3L scores and b\/tsDMARD monotherapy were associated with a higher likelihood of achieving MDA. Among MDA\/VLDA nonachievers, 23.10% (398\/1723) and 10.24% (236\/2304) missed MDA\/VLDA achievement by 1 criterion, respectively. At the follow-up registry visit, pain was the most commonly unmet criterion across the overall MDA nonachiever (95.41%) and VLDA nonachiever (87.02%) cohorts. Other commonly unmet criteria were the patient global assessment of arthritis and psoriasis (MDA nonachievers, 89.32%; VLDA nonachievers, 75.87%) and Health Assessment Questionnaire\u2013Disability Index (MDA nonachievers, 80.91%; VLDA nonachievers, 67.01%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Despite receiving b\/tsDMARD treatment for PsA, most patients did not achieve MDA or VLDA, the most commonly unmet criteria being pain and other patient-reported outcomes. These findings indicate opportunities to improve PsA management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3899\/jrheum.2025-1171","type":"journal-article","created":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T12:25:20Z","timestamp":1785587120000},"page":"jrheum.2025-1171","source":"Crossref","is-referenced-by-count":0,"title":["Who Achieves Minimal and Very Low Disease Activity in Psoriatic Arthritis? An Analysis of the CorEvitas Psoriatic Arthritis\/Spondyloarthritis Registry"],"prefix":"10.3899","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4639-0775","authenticated-orcid":false,"given":"Alexis","family":"Ogdie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6909-7195","authenticated-orcid":false,"given":"Chao","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Middaugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1915-5793","authenticated-orcid":false,"given":"Maya","family":"Marchese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3280-935X","authenticated-orcid":false,"given":"Melissa","family":"Eliot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4930-4887","authenticated-orcid":false,"given":"Robert","family":"Low","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6620-0457","authenticated-orcid":false,"given":"Philip J.","family":"Mease","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2026,8,1]]},"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.2025-1171","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T12:15:18Z","timestamp":1790856918000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.2025-1171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,1]]},"references-count":0,"alternative-id":["10.3899\/jrheum.2025-1171"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.2025-1171","relation":{},"ISSN":["0315-162X","1499-2752","0315-162X"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"},{"value":"0315-162X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,1]]}}}